The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Have a look last week candle stick chart, you will see it's also pulled back 2 days after big jump, yesterday and today is the same trade pattern show last week for consolidation/profit taking.
He will be the one to make it, Although David Sturt also does very good work.
Alastair is a very successfully businessman graduate from Oxford. He speaks Chinese and has Chinese connections, he could sell PTR to Chinese.
there are 45M shares traded today, 21M buy and 24 M sale according to ADVFN. About 15% of the free float shares changed hands today.
the management clearly said they would do the RI, not placing, so all the old holders have the chance to take part in. although placing is much easier.
Phil 45,
I agree most of the investors here do their own researches. but in the real life, quite a lot stocks following under valued, full valued and over valued life span, PTR is still in first stage here. many has not realized that only L67 could value more than $100M with certain developments.
Phil45,
I think there might be long run for PTR to go.
Look at AMGO thread, how many posts a day and it's really hot.
it's so quiet here, even it's a very good operational news today.
finally crashed that over hang 2.6P by Dave now, next Barrier will be 3P, let's see we could make it till this friday.
from the chart, it seems there's a pattern, that every 4-5 trading days rise, there's a wave of profit taking, it changed this time
apologize, wrong thread.
from the chart, it seems there's a pattern, that every 4-5 trading days rise, there's a wave of profit taking, it changed this time
3.5P is the highest on the 5 year chart, let's see it could test it this week/month.
we will break this resistant today and the next one will be bigger at 15P
from one year chart, technically 12P is next resist point.
it should be back to 20-30 P rate, that's before covid-19 market rate.
"Operating profit doesnt transmit to profit after tax."
Ian.B
I am not sure how long you invested here, but your above view might not 100% correct.
NSF's operating profit is very good, that's it paid half of it as dividend, the loss in the AR is mainly caused by the goodwill written off from acquisitions. it's stated and CEO explained many times in AR and AGM.
If there's a new Institutional buyer join us, then it can show the confidence of the market for equity raising.
When Invesco was sold out at last July, HSBC bought in, moved SP from 3P up to 7.5P in 3-4 days. we know later that HSBC only trade NSF for short term profit, not the long term holder to support the business.
Maverick12,
NSF bought HC for £82.5M on 7/07/2015 from S&U
bought EL for £ 235M on 4/12/2015 from STB (36 branches at that time)
the Potential equity raise amount is a quite big amount, account to Hardman & Co's Nov 2020 report, it might be £30-55M.
i think it might separate into two slots, if the GL redress is sorted, then SP might be back to 10P and it could raise at 10P for 1;1 first, then when the market sentiment gets better with some good TU, it could raise more at much higher price.
you got the point, this sector is one of the very few business could avoid competition internationally.
that's I like to invest.